Search

Your search keyword '"Chang, Yen-Hwa"' showing total 461 results
Start Over Author "Chang, Yen-Hwa"
461 results on '"Chang, Yen-Hwa"'

2. Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial

Author

Mamtani, Ronac, Matsubara, Nobuaki, Pino, Alvaro Montesa, Herranz, Urbano Anido, Şendur, Mehmet A． N., Gravis, Gwenaelle, Huillard, Olivier, Lee, Hyo Jin, Gafanov, Rustem, Joly, Florence, Bedke, Jens, Sella, Avishay, Chang, Yen-Hwa, Imai, Kentaro, Moreno, Blanca Homet, Xu, Jin Zhi, Alva, Ajjai, and Powles, Thomas

Published
2025
Full Text
View/download PDF

4. Prediction of clinically significant prostate cancer through urine metabolomic signatures: A large-scale validated study

Author

Huang, Hsiang-Po, Chen, Chung-Hsin, Chang, Kai-Hsiung, Lee, Ming-Shyue, Lee, Cheng-Fan, Chao, Yen-Hsiang, Lu, Shih-Yu, Wu, Tzu-Fan, Liang, Sung-Tzu, Lin, Chih-Yu, Lin, Yuan Chi, Liu, Shih-Ping, Lu, Yu-Chuan, Shun, Chia-Tung, Huang, William J., Lin, Tzu-Ping, Ku, Ming-Hsuan, Chung, Hsiao-Jen, Chang, Yen-Hwa, Liao, Chun-Hou, Yu, Chih-Chin, Chung, Shiu-Dong, Tsai, Yao-Chou, Wu, Chia-Chang, Chen, Kuan-Chou, Ho, Chen-Hsun, Hsiao, Pei-Wen, and Pu, Yeong-Shiau

Published
2023
Full Text
View/download PDF

6. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Tomczak, Piotr, Choueiri, Toni, Park, Se Hoon, Venugopal, Balaji, Ferguson, Thomas R., Hajek, Jaroslav, Lin, Tzu-Ping, Symeonides, Stefan N., Lee, Jae Lyun, Sawrycki, Piotr, Haas, Naomi B., Gurney, Howard P., Mahave, Mauricio, Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Chevreau, Christine, Burke, John M., Doshi, Gurjyot, Melichar, Bohuslav, Topart, Delphine, Oudard, Stephane, Kopyltsov, Evgeniy, Hammers, Hans-Joerg, Quinn, David I., Alva, Ajjai, Menezes, Juliana de Janoski, Silva, Adriano Goncalves e, Winquist, Eric W., Hamzaj, Alketa, Procopio, Giuseppe, Karaszewska, Boguslawa, Nowakowska-Zajdel, Ewa M., Alekseev, Boris Y., Gafanov, Rustem A., Izmailov, Adel, Semenov, Andrey, Afanasyev, Sergey G., Lipatov, Oleg N., Powles, Thomas B., Srinivas, Sandy, McDermott, David, Kochuparambil, Samith T., Davis, Ian D., Peltola, Katriina, Sabbatini, Roberto, Chung, Jinsoo, Shkolnik, Michail I., Matveev, Vsevolod B., Gajate Borau, Pablo, McCune, Steven, Hutson, Thomas E., Dri, Alejandro, Sales, Silvio Correia, Yeung, Carrie, Alcala Castro, Carmen Marcela, Bostrom, Peter, Laguerre, Brigitte, Buttigliero, Consuelo, de Giorgi, Ugo, Fomin, Eugeniy A., Zakharia, Yousef, Hwang, Clara, Singer, Eric A., Yorio, Jeffrey T., Waterhouse, David, Kowalyszyn, Ruben Dario, Alfie, Margarita Sonia, Yanez Ruiz, Eduardo, Buchler, Tomas, Kankaanranta, Krista, Ferretti, Gianluigi, Kimura, Go, Nishimura, Kazuo, Masumori, Naoya, Tamada, Satoshi, Kato, Haruaki, Kitamura, Hiroshi, Danielewicz, Iwona, Wojcik-Tomaszewska, Joanna, Sala Gonzalez, Nuria, Chiu, Kun-Yuan, Atkins, Michael B., Heath, Elisabeth, Rojas-Uribe, Gustavo Adolfo, Gonzalez Fernandez, Manuel Enrique, Feyerabend, Susan, Pignata, Sandro, Numakura, Kazuyuki, Cybulska Stopa, Bozena, Zukov, Ruslan, Climent Duran, Miguel Angel, Maroto Rey, Pablo Jose, Montesa Pino, Alvaro, Chang, Chao-Hsiang, Vengalil, Salil, Waddell, Tom S., Cobb, Patrick W., Hauke, Ralph, Anderson, Daniel M., Sarantopoulos, John, Gourdin, Theodore, Zhang, Tian, Jayram, Gautam, Fein, Luis Enrique, Harris, Carole, Beato, Patricia Medeiros Milhomem, Flores, Francisco, Estay, Angela, Rubiano, Juan Andres, Bedke, Jens, Hauser, Stefan, Neisius, Andreas, Busch, Jonas, Anai, Satoshi, Tsunemori, Hiroyuki, Sawka, Dariusz, Sikora-Kupis, Bozena, Arranz, Jose Angel, Delgado, Ignacio, Chen, Chung-Hsin, Gunderson, Elizabeth, Tykodi, Scott, Koletsky, Alan, Chen, Kevin, Agrawal, Manish, Kaen, Diego Lucas, Sade, Juan Pablo, Tatangelo, Marcelo Daniel, Parnis, Francis, Barbosa, Fernando Maciel, Faucher, Genevieve, Iqbal, Nayyer, Marceau, Daniele, Paradis, Jean-Benoit, Hanna, Nawar, Acevedo, Alejandro, Ibanez, Carolina, Villanueva, Luis, Galaz, Pedro Pablo, Durango, Isabel Cristina, Manneh, Ray, Kral, Zdenek, Holeckova, Petra, Hakkarainen, Heikki, Ronkainen, Hanna, Abadie-Lacourtoisie, Sophie, Tartas, Sophie, Goebell, Peter J., Grimm, Marc-Oliver, Hoefner, Thomas, Wirth, Manfred, Panic, Andrej, Schultze-Seemann, Wolfgang, Yokomizo, Akira, Mizuno, Ryuichi, Uemura, Hirotsugu, Eto, Masatoshi, Tsujihata, Masao, Matsukawa, Yoshihisa, Murakami, Yoji, Kim, Miso, Hamberg, Paul, Marczewska-Skrodzka, Malgorzata, Szczylik, Cezary, Humphreys, Alison C., Jiang, Peter, Kumar, Birendra, Lu, Gary, Desai, Arpita, Karam, Jose Antonio, Keogh, George, Fleming, Mark, Zarba, Juan Jose, Leiva, Viviana E., Mendez, Guillermo Ariel, Harris, Samuel J., Brown, Stephen J., Antonio Junior, Joao Neif, Costamilan, Rita de Cassia, Rocha, Roberto Odebrecht, Muniz, David, Brust, Leandro, Lalani, Aly-Khan, Graham, Jeffrey, Levesque, Michael, Orlandi, Francisco, Kotasek, Rostislav, Deville, Jean L., Borchiellini, Delphine, Merseburger, Axel, Rink, Michael, Roos, Frederik, McDermott, Ray, Oyama, Masafumi, Yamamoto, Yoshiaki, Tomita, Yoshihiko, Miura, Yuji, Ioritani, Naomasa, Westgeest, Hans, Kubiatowski, Tomasz, Bal, Wieslaw, Girones Sarrio, Regina, Rowe, Julie, Prow, Debra M., Senecal, Francis, Hashemi-Sadraei, Neda, Cole, Scott W., Kendall, Stephan D., Richards, Donald A., Schnadig, Ian D., Gupta, Mukul, Powles, Thomas, Ferguson, Thomas, Symeonides, Stefan N, Gurney, Howard, Chang, Yen-Hwa, Haas, Naomi B, Burgents, Joseph E, Xu, Lei, Imai, Kentaro, Quinn, David I, and Choueiri, Toni K

Published
2022
Full Text
View/download PDF

7. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

Author

Motzer, Robert J, Ravaud, Alain, Patard, Jean-Jacques, Pandha, Hardev S, George, Daniel J, Patel, Anup, Chang, Yen-Hwa, Escudier, Bernard, Donskov, Frede, Magheli, Ahmed, Carteni, Giacomo, Laguerre, Brigitte, Tomczak, Piotr, Breza, Jan, Gerletti, Paola, Lechuga, Mariajose, Lin, Xun, Casey, Michelle, Serfass, Lucile, Pantuck, Allan J, and Staehler, Michael

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Kidney Disease, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Genetics, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Angiogenesis Inhibitors, Carcinoma, Renal Cell, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Humans, Indoles, Kaplan-Meier Estimate, Kidney Neoplasms, Male, Middle Aged, Nephrectomy, Proportional Hazards Models, Pyrroles, Risk Factors, Sunitinib, Time Factors, Treatment Outcome, Adjuvant, Disease-free survival, Renal cell carcinoma, Urology & Nephrology, Clinical sciences
Abstract

BackgroundAdjuvant sunitinib significantly improved disease-free survival (DFS) versus placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence after nephrectomy (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.59-0.98; p=0.03).ObjectiveTo report the relationship between baseline factors and DFS, pattern of recurrence, and updated overall survival (OS).Design, setting, and participantsData for 615 patients randomized to sunitinib (n=309) or placebo (n=306) in the S-TRAC trial.Outcome measurements and statistical analysisSubgroup DFS analyses by baseline risk factors were conducted using a Cox proportional hazards model. Baseline risk factors included: modified University of California Los Angeles integrated staging system criteria, age, gender, Eastern Cooperative Oncology Group performance status (ECOG PS), weight, neutrophil-to-lymphocyte ratio (NLR), and Fuhrman grade.Results and limitationsOf 615 patients, 97 and 122 in the sunitinib and placebo arms developed metastatic disease, with the most common sites of distant recurrence being lung (40 and 49), lymph node (21 and 26), and liver (11 and 14), respectively. A benefit of adjuvant sunitinib over placebo was observed across subgroups, including: higher risk (T3, no or undetermined nodal involvement, Fuhrman grade ≥2, ECOG PS ≥1, T4 and/or nodal involvement; hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.55-0.99; p=0.04), NLR ≤3 (HR 0.72, 95% CI 0.54-0.95; p=0.02), and Fuhrman grade 3/4 (HR 0.73, 95% CI 0.55-0.98; p=0.04). All subgroup analyses were exploratory, and no adjustments for multiplicity were made. Median OS was not reached in either arm (HR 0.92, 95% CI 0.66-1.28; p=0.6); 67 and 74 patients died in the sunitinib and placebo arms, respectively.ConclusionsA benefit of adjuvant sunitinib over placebo was observed across subgroups. The results are consistent with the primary analysis, which showed a benefit for adjuvant sunitinib in patients at high risk of recurrent RCC after nephrectomy.Patient summaryMost subgroups of patients at high risk of recurrent renal cell carcinoma after nephrectomy experienced a clinical benefit with adjuvant sunitinib.Trial registrationClinicalTrials.gov NCT00375674.

Published
2018

8. PD20-12 NEOADJUVANT THERAPY IN INITIALLY INOPERABLE UPPER TRACT UROTHELIAL CARCINOMA—A COMPARATIVE STUDY WITH ADJUVANT STRATEGIES

Author

Huang, Yu-Kai, primary, Yi-Hsiu Huang, Eric, additional, Teng-Lung Lin, Alex, additional, Chang, Yen-Hwa, additional, Chung, Hsiao-Jen, additional, Lin, Tzu-Ping, additional, Lin, Chih-Chieh, additional, Chen, Wei-Jen, additional, Ku, Ming-Hsuan, additional, Huang, William J. S., additional, Yen, Chueh-Chuan, additional, Mu-Hsin Chang, Peter, additional, and Lai, Jiun-I, additional

Published
2024
Full Text
View/download PDF

9. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Author

Choueiri, Toni K., primary, Tomczak, Piotr, additional, Park, Se Hoon, additional, Venugopal, Balaji, additional, Ferguson, Tom, additional, Symeonides, Stefan N., additional, Hajek, Jaroslav, additional, Chang, Yen-Hwa, additional, Lee, Jae-Lyun, additional, Sarwar, Naveed, additional, Haas, Naomi B., additional, Gurney, Howard, additional, Sawrycki, Piotr, additional, Mahave, Mauricio, additional, Gross-Goupil, Marine, additional, Zhang, Tian, additional, Burke, John M., additional, Doshi, Gurjyot, additional, Melichar, Bohuslav, additional, Kopyltsov, Evgeniy, additional, Alva, Ajjai, additional, Oudard, Stephane, additional, Topart, Delphine, additional, Hammers, Hans, additional, Kitamura, Hiroshi, additional, McDermott, David F., additional, Silva, Adriano, additional, Winquist, Eric, additional, Cornell, Jerry, additional, Elfiky, Aymen, additional, Burgents, Joseph E., additional, Perini, Rodolfo F., additional, and Powles, Thomas, additional

Published
2024
Full Text
View/download PDF

11. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Author

Cascallar, Diana Vera, Varela, Mirta, Lazzaro, Mauricio Fernandez, Kaen, Diego Lucas, Gatica, Gabriela, Flores, David Hugo, Falco, Agustin, Molina, Matias, Van Aelst, Filip, Vulsteke, Christof, Sautois, Brieuc, Machiels, Jean-Pascal, Schallier, Denis, Brust, Leandro, Rapatoni, Liane, Azevedo, Sergio J, Marinho, Gisele, Soares, Joao Paulo Holanda, Dzik, Carlos, Almeida Silva, Jamile, Fay, Andre Poisl, Gingerich, Joel, Fradet, Yves, Ferrario, Cristiano, Potvin, Kylea, Vanhuyse, Marie, Abdelsalam, Mahmoud, Cheng, Susanna, Caglevic, Christian, Reyes, Felipe, Leal, Jose Luis, Francisco, Francisco, Ibanez, Carolina, Joly, Florence, Laguerre, Brigitte, Ladoire, Sylvain, Flechon, Aude, Topart, Delphine, Huillard, Olivier, Oudard, Stéphane, Gross-Goupil, Marine, Culine, Stephane, Loriot, Yohann, Gravis, Gwenaelle, Reichardt, Peter, Retz, Margitta, Herden, Jan, Pfister, David, Ohlman, Carsten, Stoeckle, Michael, Wirth, Manfred, Lorch, Anja, Niegisch, Guenter, Goebell, Peter J, Boegemann, Martin, Merseburger, Axel, Gakis, Georgios, Bedke, Jens, Neisius, Andreas, Thomas, Christian, Hoefner, Thomas, Telekes, Andras, Kosa, Judit Erzsebet, Revesz, Janos, Bodoky, Gyorgy, Csoszi, Tibor, Csejtei, Andras, Geczi, Lajos, Ruzsa, Agnes, Kolonics, Zsuzsanna, Erfan, Jozsef, McDermott, Ray, Bambury, Richard, Sella, Avishay, Frank, Stephen Jay, Kejzman, Daniel, Goldman, Olesya, Rosenbaum, Eli, Peer, Avivit, Berger, Raanan, Rouvinov, Keren, Sarid, David, Fukasawa, Satoshi, Arai, Gaku, Yamaguchi, Akito, Yokomizo, Akira, Takayama, Tatsuya, Kinoshita, Hidefumi, Kikuchi, Eiji, Mizuno, Ryuichi, Fujii, Yasuhisa, Sassa, Naoto, Matsukawa, Yoshihisa, Fujimoto, Kiyohide, Matsubara, Nobuaki, Tanikawa, Toshiki, Tomita, Yoshihiko, Nishimura, Kazuo, Tsujihata, Masao, Oyama, Masafumi, Masumori, Naoya, Kanayama, Hiroomi, Takano, Toshimi, Miura, Yuji, Miyazaki, Jun, Joraku, Akira, Kimura, Tomokazu, Yamamoto, Yoshiaki, Kobayashi, Kazuki, De Wit, Ronald, Aarts, Maureen, Gerritsen, Winald, Los, Maartje, Beerepoot, Laurens, Izmailov, Adel, Gorelov, Sergey Igorevich, Alekseev, Boris Yakovlevich, Semenov, Andrey, Kostorov, Vladimir Anatolyevich, Alekseev, Sergey M, Zyryanov, Alexander, Oschepkov, Vasiliy Nikolaevich, Shidin, Vladimir Aleksandrovich, Vladimirov, Vladimir Ivanovich, Gafanov, Rustem Airatovich, Karlov, Petr Alexandrovich, Anderson, David Brian, Shepherd, Lucinda, Cohen, Graham Lawrence, Rapoport, Bernardo Louis, Ruff, Paul, Lee, Nari, Bae, Woo Kyun, Lee, Hyo Jin, Herranz, Urbano Anido, Rodriguez-Vida, Alejo, Morales Barrera, Rafael, Grande, Enrique, Alonso Gordoa, Teresa, Guma Padro, Josep, Gauna, Daniel Castellano, Arranz, Jose Angel, Munoz Langa, Jose, Sarrio, Regina Girones, Montesa Pino, Alvaro, Juan Fita, Maria Jose, Su, Yu-Li, Lin, Yung-Chang, Su, Wen-Pin, Shen, Ying-Chun, Chang, Yen-Hwa, Huang, Yi-Hsiu, Sriuranpong, Virote, Chansriwong, Phichai, Srimuninnimit, Vichien, Danchaivijitr, Pongwut, Abali, Huseyin, Yavuz, Sinan, Ozyilkan, Ozgur, Sendur, Mehmet Ali Nahit, Ekenel, Meltem, Ozguroglu, Mustafa, Arslan, Cagatay, Gunduz, Seyda, Ozdogan, Mustafa, Birtle, Alison, Powles, Thomas, Huddart, Robert, de Santis, Maria, Zarkar, Anjali, Evans, Linda, Hussain, Syed, DiSimone, Christopher, Muina, Antonio F, Schlegel, Peter, Jhangiani, Haresh S, Harrison, Michael, Slater, Dennis E, Wright, David, Percent, Ivor J, Lin, Jianqing, Hwang, Clara, Mamtani, Ronac, Gupta, Sumati, Bajaj, Madhuri, Galamaga, Robert, Eklund, John, Wallace, James, Shtivelband, Mikhail, Suh, Jason Jung-Gon, Burhani, Nafisa, Eadens, Matthew, Gunturu, Krishna, Burgess, Earle, Wong, John, Chaudhry, Arvind, Van Veldhuizen, Peter, Graff, Stephanie, Thomas, Christian A, Schnadig, Ian D, Carneiro, Benedito, Hussain, Maha, Morgans, Alicia, Fitzharris, John T, Oliff, Ira A, Vuky, Jacqueline, Hauke, Ralph, Baron, Ari, Joshi, Monika, Bolemon, Britt H, Jiang, Peter, Mega, Anthony E, Markus, Maurice, Pfanzelter, Nicklas, Lawler, William Eyre, Cobb, Patrick Wayne, Courtright, Jay G, Jain, Sharad, Doshi, Gurjyot, Gunuganti, Vijay K, Sartor, Oliver Alton, Cole, Scott W, Babiker, Hani, Uchio, Edward M, Drakaki, Alexandra, Mannuel, Heather D, Alva, Ajjai, Guancial, Elizabeth, Fung, Chunkit, Charles, Anthony, Amato, Robert J, Arriaga, Yull, Bowman, Isaac, Ades, Steven, Dreicer, Robert, Yu, Evan, Quinn, David I, Fleming, Mark, Csőszi, Tibor, Özgüroğlu, Mustafa, Géczi, Lajos, Cheng, Susanna Y-S, Oudard, Stephane, Fléchon, Aude, Yu, Evan Y, Nam, Kijoeng, Imai, Kentaro, and Homet Moreno, Blanca

Published
2021
Full Text
View/download PDF

12. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Park, Se Hoon, van der Heijden, Michiel S., Necchi, Andrea, Castellano, Daniel, Bamias, Aristotelis, Lee, Jae Lyun, De Giorgi, Ugo, Bögemann, Martin, Eigl, Bernhard J., Tsiatas, Marinos, Powles, Thomas, Novikov, Andrey, Skoneczna, Iwona, Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Fradet, Yves, Flechon, Aude, Ou, Yen-Chuan, Park, Inkeun, Matveev, Vsevolod, Pérez-Valderrama, Begoña, Cheng, Susanna, Frank, Stephen, Gurney, Howard, Anido, Urbano, Hamzaj, Alketa, Retz, Margitta, Sridhar, Srikala, Scagliotti, Giorgio Vittorio, Voortman, Jens, Alekseev, Boris, Alyasova, Anna, Komyakov, Boris, Dumez, Herlinde, Pavic, Michel, Kimura, Go, Mizokami, Atsushi, Osanto, Susanne, Arranz, Jose Angel, Piersma, Djura, Shin, Sang Joon, Karyakin, Oleg, Delgado, Ignacio, Gonzalez, Jose Luis, Pang, See-Tong, Tran, Anna, Lipatov, Oleg, Su, Wen-Pin, Flaig, Thomas, Alva, Ajjai, Park Kyong, Hwa, Kopyltsov, Evgeny, Almagro, Elena, Domenech, Monserrat, Chang, Yen-Hwa, Sautois, Brieuc, Ravaux, Andre, Aravantinos, Gerasimos, Georgoulias, Vasileios, Mulder, Sasja, Kim, Yu Jung, Kater, Fabio, Chevreau, Christine, Tagawa, Scott, Zalewski, Pawel, Joly, Florence, Loriot, Yohann, Hatiboglu, Gencay, Gianni, Luca, Morelli, Franco, Tambaro, Rosa, Hashimoto, Yasuhiro, Nosov, Alexander, Font, Albert, Rodriguez-Vida, Alejo M., Jones, Robert, Vasudev, Naveen, Srinivas, Sandhya, Zhang, Jingsong, Gil, Thierry, Finch, Daygen, Grimm, Marc-Oliver, Su, Yu-Li, Chowdhury, Simon, Hocking, Christopher, Plas, Eugen, North, Scott, Jensen, Niels Viggo, Theodore, Christine, Imkamp, Florian, Peer, Avivit, Kobayashi, Takashi, Sakai, Hideki, Sassa, Naoto, Yoshimura, Kazuhiro, Aarts, Maureen, Ferreira Castro, Ana, Topuzov, Marlen, Rodriguez, Juan Francisco, Vazquez, Federico Jose, Tsai, Yu-Chieh, Crabb, Simon, Hussain, Syed, Bendell, Johanna, Gross-Goupil, Marine, Gwenaelle, Gravis, Berger, Raanan, Statsenko, Galina, Evans, Linda, Drakaki, Alexandra, Somer, Bradley, Davis, Ian, Lynam, James, Borges, Giuliano, Dettino, Aldo, Fay, André P., Martins, Graziella, Zucca, Luis Eduardo, Agerbaek, Mads, Kalofonos, Haralambos, Rosenbaum, Eli, Enokida, Hideki, Kikukawa, Hiroaki, Nishimura, Kazuo, Tamada, Satoshi, Uemura, Motohide, Lopez, Yamil, Gietema, Jourik, Slojewski, Marcin, Fernandes, Isabel, Smolin, Alexey, Mazhar, Danish, Kalebasty, Arash Rezazadeh, Carthon, Bradley, Loidl, Wolfgang, Franke, Fabio, Girotto, Gustavo, Alimohamed, Nimira, Macfarlane, Robyn, Pappot, Helle, Niegisch, Guenter, Mavroudis, Dimitrios, Sella, Avishay, Porta, Camillo, Ebara, Shin, Nakamura, Motonobu, Obara, Wataru, Okuno, Norihiko, Shinohara, Nobuo, Sugimoto, Mikio, Suzuki, Akitaka, Tokuda, Noriaki, Uemura, Hiroji, Yamaguchi, Akito, Ramirez, Francisco, Rozanowski, Pawel, Wiechno, Pawel, Keam, Bhumsuk, Kislov, Nikolay, Plaksin, Denis, Cicin, Irfan, Kumar, Satish, Galsky, Matthew D., Petrylak, Daniel P., Rosales, Joseph, Vaishampayan, Ulka, Culine, Stephane, Papandreou, Christos, Nara, Taketoshi, Erman, Mustafa, Kreiger, Laurence, Janoski, Juliana, Rosa, Diogo, Siqueira, Mariana, Canil, Christina, Sengelov, Lisa, Tourani, Jean-Marc, Arai, Gaku, Hashine, Katsuyoshi, Kawakita, Mutsushi, Nakaigawa, Noboru, Nomi, Hayahito, Shiina, Hiroaki, Suzuki, Hiroyoshi, Yonese, Junji, Kuri, Roberto, Macedo, Eleazar, Rivera, Samuel, Villalobos Prieto, Alberto, Polakiewicz-Gilowska, Anna, Zaucha, Renata, Lopes, Fabio, Ponomarev, Roman, Pomerantz, Mark, Shariat, Shahrokh, Luk, Cynthia, Lesniewski-Kmak, Krzysztof, van der Heijden, Michiel S, Galsky, Matthew D, Petrylak, Daniel P, Ogawa, Osamu, Lee, Jae-Lyun, Eigl, Bernhard J, Mukherjee, Som D, Suárez, Cristina, Fay, André P, Duran, Ignacio, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, and Bellmunt, Joaquim

Published
2020
Full Text
View/download PDF

13. ADJUVANT PEMBROLIZUMAB FOR RENAL CELL CARCINOMA (KEYNOTE-564): EXPLORATORY ANALYSIS ACROSS UCLA INTEGRATED STAGING SYSTEM RISK GROUPS AND DISEASE STAGE

Author

Zhang, Tian, primary, Choueiri, Toni K., additional, Tomczak, Piotr, additional, Park, Se Hoon, additional, Venugopal, Balaji, additional, Ferguson, Tom, additional, Symeonides, Stefan N., additional, Hajek, Jaroslav, additional, Chang, Yen-Hwa, additional, Lee, Jae-Lyun, additional, Sarwar, Naveed, additional, Thiery-Vuillemin, Antoine, additional, Gross-Goupil, Marine, additional, Mahave, Mauricio, additional, Haas, Naomi B., additional, Sawrycki, Piotr, additional, Xu, Lei, additional, Imai, Kentaro, additional, Poehlein, Christian, additional, and Powles, Thomas, additional

Published
2024
Full Text
View/download PDF

16. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

Author

Plimack, Elizabeth R., primary, Powles, Thomas, additional, Stus, Viktor, additional, Gafanov, Rustem, additional, Nosov, Dmitry, additional, Waddell, Tom, additional, Alekseev, Boris, additional, Pouliot, Frédéric, additional, Melichar, Bohuslav, additional, Soulières, Denis, additional, Borchiellini, Delphine, additional, McDermott, Raymond S., additional, Vynnychenko, Ihor, additional, Chang, Yen-Hwa, additional, Tamada, Satoshi, additional, Atkins, Michael B., additional, Li, Chenxiang, additional, Perini, Rodolfo, additional, Molife, L. Rhoda, additional, Bedke, Jens, additional, and Rini, Brian I., additional

Published
2023
Full Text
View/download PDF

18. Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)]

Author

Plimack, Elizabeth R., primary, Powles, Thomas, additional, Stus, Viktor, additional, Gafanov, Rustem, additional, Nosov, Dmitry, additional, Waddell, Tom, additional, Alekseev, Boris, additional, Pouliot, Frédéric, additional, Melichar, Bohuslav, additional, Soulières, Denis, additional, Borchiellini, Delphine, additional, McDermott, Raymond S., additional, Vynnychenko, Ihor, additional, Chang, Yen-Hwa, additional, Tamada, Satoshi, additional, Atkins, Michael B., additional, Li, Chenxiang, additional, Perini, Rodolfo, additional, Rhoda Molife, L., additional, Bedke, Jens, additional, and Rini, Brian I., additional

Published
2023
Full Text
View/download PDF

19. Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Author

Choueiri, Toni K, primary, Tomczak, Piotr, additional, Park, Se Hoon, additional, Venugopal, Balaji, additional, Symeonides, Stefan, additional, Hajek, Jaroslav, additional, Ferguson, Thomas, additional, Chang, Yen-Hwa, additional, Lee, Jae Lyun, additional, Haas, Naomi, additional, Sawrycki, Piotr, additional, Sarwar, Naveed, additional, Gross-Goupil, Marine, additional, Thiery-Vuillemin, Antoine, additional, Mahave, Mauricio, additional, Kimura, Go, additional, Perini, Rodolfo F, additional, Saretsky, Todd L, additional, Bhattacharya, Rituparna, additional, Xu, Lei, additional, and Powles, Thomas, additional

Published
2023
Full Text
View/download PDF

26. Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).

Author

Choueiri, Toni K., Tomczak, Piotr, Park, Se Hoon, Venugopal, Balaji, Ferguson, Thomas, Symeonides, Stefan N., Hajek, Jaroslav, Chang, Yen-Hwa, Lee, Jae-Lyun, Sarwar, Naveed, Gurney, Howard, Gross-Goupil, Marine, Mahave, Mauricio, Haas, Naomi B., Sawrycki, Piotr, Zhang, Tian, Cornell, Jerry, Elfiky, Aymen, Burgents, Joseph E., and Powles, Thomas

Published
2024
Full Text
View/download PDF

27. Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.

Author

Choueiri, Toni K, Tomczak, Piotr, Park, Se Hoon, Venugopal, Balaji, Symeonides, Stefan, Hajek, Jaroslav, Ferguson, Thomas, Chang, Yen-Hwa, Lee, Jae Lyun, Haas, Naomi, Sawrycki, Piotr, Sarwar, Naveed, Gross-Goupil, Marine, Thiery-Vuillemin, Antoine, Mahave, Mauricio, Kimura, Go, Perini, Rodolfo F, Saretsky, Todd L, Bhattacharya, Rituparna, and Xu, Lei

Subjects
RENAL cell carcinoma, CONFIDENCE intervals, NEPHRECTOMY, HEALTH outcome assessment, HEALTH status indicators, QUALITY of life, RESEARCH funding, DESCRIPTIVE statistics
Abstract

Background In patients with renal cell carcinoma (RCC) enrolled in the phase III KEYNOTE-564 trial (NCT03142334), disease-free survival (DFS) following nephrectomy was prolonged with use of adjuvant pembrolizumab therapy versus placebo. Patient-reported outcomes (PROs) provide an important measure of health-related quality of life (HRQoL) and can complement efficacy and safety results. Patients and Methods In KEYNOTE-564, 994 patients were randomly assigned to receive pembrolizumab 200 mg (n  = 496) or placebo (n  = 498) intravenously every 3 weeks for ≤17 cycles. Patients who received ≥1 dose of treatment and completed ≥1 HRQoL assessment were included in this analysis. HRQoL end points were assessed using the EORTC QLQ-C30, FKSI-DRS, and EQ VAS. Prespecified and exploratory PRO end points were mean change from baseline in EORTC QLQ-C30 GHS/QoL score, EORTC QLQ-C30 physical function subscale score, and FKSI-DRS score. Results No clinically meaningful difference in least squares mean scores for pembrolizumab versus placebo were observed at week 52 for EORTC QLQ-C30 GHS/QoL (–2.5; 95% CI –5.2 to 0.1), EORTC QLQ-C30 physical functioning (–0.87; 95% CI –2.7 to 1.0), and FKSI-DRS (–0.7; 95% CI –1.2 to –0.1). Most PRO scores remained stable or improved for the EORTC QLQ-C30 GHS/QoL (pembrolizumab, 54.3%; placebo, 67.5%), EORTC QLQ-C30 physical functioning (pembrolizumab, 64.7%; placebo, 68.8%), and FKSI-DRS (pembrolizumab, 58.2%; placebo, 66.3%). Conclusions Adjuvant treatment with pembrolizumab did not result in deterioration of HRQoL. These findings together with the safety and efficacy findings support adjuvant pembrolizumab treatment following nephrectomy. Trial Registration Clinicaltrials.gov Identifier: NCT03142334 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. MP69-12 THE PREDICTION OF RENAL FUNCTION CHANGE AFTER UNILATERAL NEPHROURETERECTOMY IN UPPER TRACT UROTHELIAL CARCINOMA PATIENTS BY USING TC-99M MAG3 RENAL SCAN

Author

Su, Kai-Sen, primary, Huang, Yi-Hsiu, additional, Ku, Ming-Hsuan, additional, Chen, Wei-Ren, additional, Huang, Tzu-Hao, additional, Wei, Tzu-Chun, additional, Huang, I-Shen, additional, Fan, Yu-Hua, additional, Lin, Chih-Chieh, additional, Lin, Tzu-Ping, additional, Chung, Hsiao-Jen, additional, Kuo, Junne-Yih, additional, Chang, Yen-Hwa, additional, Lin, Teng-Lung, additional, Huang, Jhih-Sian, additional, and Chen, Jen-Chieh, additional

Published
2023
Full Text
View/download PDF

35. Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study.

Author

Choueiri, Toni K., primary, Tomczak, Piotr, additional, Park, Se Hoon, additional, Venugopal, Balaji, additional, Ferguson, Tom, additional, Symeonides, Stefan N., additional, Hajek, Jaroslav, additional, Chang, Yen-Hwa, additional, Lee, Jae-Lyun, additional, Sarwar, Naveed, additional, Thiery-Vuillemin, Antoine, additional, Gross-Goupil, Marine, additional, Mahave, Mauricio, additional, Haas, Naomi B., additional, Sawrycki, Piotr, additional, Zhang, Tian, additional, Xu, Lei, additional, Imai, Kentaro, additional, Poehlein, Christian Heinrich, additional, and Powles, Thomas, additional

Published
2023
Full Text
View/download PDF

36. Is Robotic Superior to Laparoscopic Approach for Radical Nephroureterectomy with Bladder Cuff Excision in Treating Upper Urinary Tract Urothelial Carcinoma?

Author

Huang, Yu-Pin, primary, Huang, Eric Yi-Hsiu, additional, Chung, Hsiao-Jen, additional, Tai, Meng-Che, additional, Huang, Tzu-Hao, additional, Wei, Tzu-Chun, additional, Fan, Yu-Hua, additional, Lin, Chih-Chieh, additional, Lin, Tzu-Ping, additional, Kuo, Junne-Yih, additional, Lu, Shing-Hwa, additional, Chang, Yen-Hwa, additional, Lin, Alex Tong-Lung, additional, and Huang, William Ji-Sien, additional

Published
2023
Full Text
View/download PDF

38. Combining prostate health index and multiparametric magnetic resonance imaging may better predict extraprostatic extension after radical prostatectomy

Author

Huang, Yu-Pin, primary, Lin, Tzu-Ping, additional, Shen, Shu-Huei, additional, Cheng, Wei-Ming, additional, Huang, Tzu-Hao, additional, Huang, I-Shen, additional, Fan, Yu-Hua, additional, Lin, Chih-Chieh, additional, Huang, Eric Y. H., additional, Chung, Hsiao-Jen, additional, Lu, Shing-Hwa, additional, Chang, Yen-Hwa, additional, Lin, Alex T. L., additional, and Huang, William J., additional

Published
2022
Full Text
View/download PDF

41. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

Author

Guo, Jun, Jin, Jie, Oya, Mototsugu, Uemura, Hirotsugu, Takahashi, Shunji, Tatsugami, Katsunori, Rha, Sun Young, Lee, Jae-Lyun, Chung, Jinsoo, Lim, Ho Yeong, Wu, Hsi Chin, Chang, Yen Hwa, Azad, Arun, Davis, Ian D., Carrasco-Alfonso, Marlene J., Nanua, Bhupinder, Han, Jackie, Ahmad, Qasim, and Motzer, Robert

Published
2018
Full Text
View/download PDF

42. The comparison of different BCG strains in the intravesical treatment of non-muscle invasive urothelial carcinoma of urinary bladder-A real-world practice

Author

Chen, Yu-Kuang, primary, Huang, Eric Yi-Hsiu, additional, Chang, Yen-Hwa, additional, Kuo, Junne-Yih, additional, Chung, Hsiao-Jen, additional, Wu, Howard Hung-Hao, additional, Lin, Tzu-Ping, additional, Lin, Chih-Chieh, additional, Fan, Yu-Hua, additional, Huang, I-Shen, additional, Lin, Alex T.L., additional, and Huang, William J., additional

Published
2022
Full Text
View/download PDF

43. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Powles, Thomas, primary, Tomczak, Piotr, additional, Park, Se Hoon, additional, Venugopal, Balaji, additional, Ferguson, Thomas, additional, Symeonides, Stefan N, additional, Hajek, Jaroslav, additional, Gurney, Howard, additional, Chang, Yen-Hwa, additional, Lee, Jae Lyun, additional, Sarwar, Naveed, additional, Thiery-Vuillemin, Antoine, additional, Gross-Goupil, Marine, additional, Mahave, Mauricio, additional, Haas, Naomi B, additional, Sawrycki, Piotr, additional, Burgents, Joseph E, additional, Xu, Lei, additional, Imai, Kentaro, additional, Quinn, David I, additional, Choueiri, Toni K, additional, Choueiri, Toni, additional, Ferguson, Thomas R., additional, Lin, Tzu-Ping, additional, Symeonides, Stefan N., additional, Haas, Naomi B., additional, Gurney, Howard P., additional, Chevreau, Christine, additional, Burke, John M., additional, Doshi, Gurjyot, additional, Melichar, Bohuslav, additional, Topart, Delphine, additional, Oudard, Stephane, additional, Kopyltsov, Evgeniy, additional, Hammers, Hans-Joerg, additional, Quinn, David I., additional, Alva, Ajjai, additional, Menezes, Juliana de Janoski, additional, Silva, Adriano Goncalves e, additional, Winquist, Eric W., additional, Hamzaj, Alketa, additional, Procopio, Giuseppe, additional, Karaszewska, Boguslawa, additional, Nowakowska-Zajdel, Ewa M., additional, Alekseev, Boris Y., additional, Gafanov, Rustem A., additional, Izmailov, Adel, additional, Semenov, Andrey, additional, Afanasyev, Sergey G., additional, Lipatov, Oleg N., additional, Powles, Thomas B., additional, Srinivas, Sandy, additional, McDermott, David, additional, Kochuparambil, Samith T., additional, Davis, Ian D., additional, Peltola, Katriina, additional, Sabbatini, Roberto, additional, Chung, Jinsoo, additional, Shkolnik, Michail I., additional, Matveev, Vsevolod B., additional, Gajate Borau, Pablo, additional, McCune, Steven, additional, Hutson, Thomas E., additional, Dri, Alejandro, additional, Sales, Silvio Correia, additional, Yeung, Carrie, additional, Alcala Castro, Carmen Marcela, additional, Bostrom, Peter, additional, Laguerre, Brigitte, additional, Buttigliero, Consuelo, additional, de Giorgi, Ugo, additional, Fomin, Eugeniy A., additional, Zakharia, Yousef, additional, Hwang, Clara, additional, Singer, Eric A., additional, Yorio, Jeffrey T., additional, Waterhouse, David, additional, Kowalyszyn, Ruben Dario, additional, Alfie, Margarita Sonia, additional, Yanez Ruiz, Eduardo, additional, Buchler, Tomas, additional, Kankaanranta, Krista, additional, Ferretti, Gianluigi, additional, Kimura, Go, additional, Nishimura, Kazuo, additional, Masumori, Naoya, additional, Tamada, Satoshi, additional, Kato, Haruaki, additional, Kitamura, Hiroshi, additional, Danielewicz, Iwona, additional, Wojcik-Tomaszewska, Joanna, additional, Sala Gonzalez, Nuria, additional, Chiu, Kun-Yuan, additional, Atkins, Michael B., additional, Heath, Elisabeth, additional, Rojas-Uribe, Gustavo Adolfo, additional, Gonzalez Fernandez, Manuel Enrique, additional, Feyerabend, Susan, additional, Pignata, Sandro, additional, Numakura, Kazuyuki, additional, Cybulska Stopa, Bozena, additional, Zukov, Ruslan, additional, Climent Duran, Miguel Angel, additional, Maroto Rey, Pablo Jose, additional, Montesa Pino, Alvaro, additional, Chang, Chao-Hsiang, additional, Vengalil, Salil, additional, Waddell, Tom S., additional, Cobb, Patrick W., additional, Hauke, Ralph, additional, Anderson, Daniel M., additional, Sarantopoulos, John, additional, Gourdin, Theodore, additional, Zhang, Tian, additional, Jayram, Gautam, additional, Fein, Luis Enrique, additional, Harris, Carole, additional, Beato, Patricia Medeiros Milhomem, additional, Flores, Francisco, additional, Estay, Angela, additional, Rubiano, Juan Andres, additional, Bedke, Jens, additional, Hauser, Stefan, additional, Neisius, Andreas, additional, Busch, Jonas, additional, Anai, Satoshi, additional, Tsunemori, Hiroyuki, additional, Sawka, Dariusz, additional, Sikora-Kupis, Bozena, additional, Arranz, Jose Angel, additional, Delgado, Ignacio, additional, Chen, Chung-Hsin, additional, Gunderson, Elizabeth, additional, Tykodi, Scott, additional, Koletsky, Alan, additional, Chen, Kevin, additional, Agrawal, Manish, additional, Kaen, Diego Lucas, additional, Sade, Juan Pablo, additional, Tatangelo, Marcelo Daniel, additional, Parnis, Francis, additional, Barbosa, Fernando Maciel, additional, Faucher, Genevieve, additional, Iqbal, Nayyer, additional, Marceau, Daniele, additional, Paradis, Jean-Benoit, additional, Hanna, Nawar, additional, Acevedo, Alejandro, additional, Ibanez, Carolina, additional, Villanueva, Luis, additional, Galaz, Pedro Pablo, additional, Durango, Isabel Cristina, additional, Manneh, Ray, additional, Kral, Zdenek -, additional, Holeckova, Petra, additional, Hakkarainen, Heikki, additional, Ronkainen, Hanna, additional, Abadie-Lacourtoisie, Sophie, additional, Tartas, Sophie, additional, Goebell, Peter J., additional, Grimm, Marc-Oliver, additional, Hoefner, Thomas, additional, Wirth, Manfred, additional, Panic, Andrej, additional, Schultze-Seemann, Wolfgang, additional, Yokomizo, Akira, additional, Mizuno, Ryuichi, additional, Uemura, Hirotsugu, additional, Eto, Masatoshi, additional, Tsujihata, Masao, additional, Matsukawa, Yoshihisa, additional, Murakami, Yoji, additional, Kim, Miso, additional, Hamberg, Paul, additional, Marczewska-Skrodzka, Malgorzata, additional, Szczylik, Cezary, additional, Humphreys, Alison C., additional, Jiang, Peter, additional, Kumar, Birendra, additional, Lu, Gary, additional, Desai, Arpita, additional, Karam, Jose Antonio, additional, Keogh, George, additional, Fleming, Mark, additional, Zarba, Juan Jose, additional, Leiva, Viviana E., additional, Mendez, Guillermo Ariel, additional, Harris, Samuel J., additional, Brown, Stephen J., additional, Antonio Junior, Joao Neif, additional, Costamilan, Rita de Cassia, additional, Rocha, Roberto Odebrecht, additional, Muniz, David, additional, Brust, Leandro, additional, Lalani, Aly-Khan, additional, Graham, Jeffrey, additional, Levesque, Michael, additional, Orlandi, Francisco, additional, Kotasek, Rostislav, additional, Deville, Jean L., additional, Borchiellini, Delphine, additional, Merseburger, Axel, additional, Rink, Michael, additional, Roos, Frederik, additional, McDermott, Ray, additional, Oyama, Masafumi, additional, Yamamoto, Yoshiaki, additional, Tomita, Yoshihiko, additional, Miura, Yuji, additional, Ioritani, Naomasa, additional, Westgeest, Hans, additional, Kubiatowski, Tomasz, additional, Bal, Wieslaw, additional, Girones Sarrio, Regina, additional, Rowe, Julie, additional, Prow, Debra M., additional, Senecal, Francis, additional, Hashemi-Sadraei, Neda, additional, Cole, Scott W., additional, Kendall, Stephan D., additional, Richards, Donald A., additional, Schnadig, Ian D., additional, and Gupta, Mukul, additional

Published
2022
Full Text
View/download PDF

49. Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564.

Author

Choueiri, Toni K., primary, Tomczak, Piotr, additional, Park, Se Hoon, additional, Venugopal, Balaji, additional, Ferguson, Tom, additional, Symeonides, Stefan N., additional, Hajek, Jaroslav, additional, Chang, Yen-Hwa, additional, Lee, Jae-Lyun, additional, Sarwar, Naveed, additional, Thiery-Vuillemin, Antoine, additional, Gross-Goupil, Marine, additional, Mahave, Mauricio, additional, Haas, Naomi B., additional, Sawrycki, Piotr, additional, Gurney, Howard, additional, Xu, Lei, additional, Imai, Kentaro, additional, Rogerio, Jackie, additional, and Powles, Thomas, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results